Disclosures: The following people have nothing to disclose: Khaleel M. Jamil, Kuldeep S. Cheent, Michael A. Heneghan, Marco Purbhoo, Salim I. Khakoo Aim: This study was conducted PF-02341066 cost to assess the validity of using serum MicroRNAs (miRNAs) as novel noninvasive biomarkers for classifying liver disease and the candied gene for molecular target therapy. Methods: MiScript miRNA PCR Arrays For SYBR Green-based, real-time PCR profiling of 13 microRNAs in 480 serum samples comprising; 192 HCC, 96 Liver Cirrhosis, 96 Chronic Hepatitis C

and 96 Healthy Control subjects. Results: We have found significant fold changes in the expression levels of miRNA genes in patient’s sera of different HCV associated liver disease when compared to the control group. In chronic hepatitis C group, we observed a significant fold increasing in the expression level of of miR-885-5p (p=0.003), miR-602 (p=0.01), miR-125a-5p (p=0.00006)″ and a significant fold decreasing in the expression levels of miR-29 (p=0.0008), miR-375 (p =0.00003). In the Cirrhotic group, we found a significant fold decreasing in the expression levels of miR-885-5p (p=0.01), miR-375 (p=0.000006), miR-22 (0.009) and miR-221 (p=0.001). In HCC group, a significant fold elevation in the expression level of miR-885-5p (p=0.03), miR-122 (p=0.021)

and significant RG7204 in vivo fold decreasing in miR-29 (p=0.007). In addition, we compared the groups with each other and there was significantly changes in expression level values of some miRNAs. In case of the cirrhotic versus the non-cirrhotic we found significant fold decreasing in the expression levels of 4 miRNAs “miR-885-5p (p=0.0002), miR-221 (p=0.02), miR-602 (p=0.04),, miR-125a-5p (p=0.008),”while with HCC versus cirrhotic, a significant fold increasing was observed in 4 miRNAs “miR-885-5p (p=0.006), miR-221 (p=0.02), miR-122 (p=0.01), miR-181 b (p=0.04).”Finally, on comparing HCC group versus non-cirrhotic group a significantly fold decreasing

was reported in two miRNAs Succinyl-CoA and noninvasive biomarkers for classifying liver disease. miR-885-5p is a potential differential marker between the infected HCV and the healthy control. In addition, miR-375 can serve as diagnostic marker for liver inflammation and cirrhosis and also may serve as a therapeutic target for HCV-positive HCC. As miR-375 targets yap protein and its mimics will inhibit hepatocarcinogensis. miR-602 and miR-125a-5p can be used for early detection of hepatocellular carcinoma and targeted for molecular therapy. Downregulation of miR-221and miR-22 can serve as potential diagnostic marker for liver cirrhosis. Disclosures: Gamal E. Esmat -Advisory Committees or Review Panels: MSD&BMS companies, MSD &BMS companies; Speaking and Teaching: Roche & GSK companies, Roche & GSK companies The following people have nothing to disclose: Abdelrahman Zekri, Amira S.